Trimebutine: Mechanism of action, effects on gastrointestinal function and clinical results

Journal of International Medical Research

Volumn 25, Issue 5, 1997, Pages 225-246

  Delvaux, M ^a   Wingate, D ^b  

^a CHU RANGUEIL   (France)

^b ROYAL LONDON HOSPITAL   (United Kingdom)

Author keywords

Children; Functional bowel disorders; Gastric motility regulators; Irritable bowel syndrome; Trimebutine

Indexed keywords

DELTA OPIATE RECEPTOR; DIGESTIVE TRACT SPASMOLYTIC AGENT; GASTRIN; GASTROINTESTINAL POLYPEPTIDE; GLUCAGON; KAPPA OPIATE RECEPTOR; MOTILIN; MU OPIATE RECEPTOR; TRIMEBUTINE; VASOACTIVE INTESTINAL POLYPEPTIDE;

ABDOMINAL PAIN; ARTICLE; CLINICAL TRIAL; COLON; GASTROINTESTINAL TRACT; HUMAN; INTESTINE; IRRITABLE COLON; META ANALYSIS; MIGRATING MYOELECTRIC COMPLEX; PROTEIN SECRETION; SMOOTH MUSCLE CONTRACTILITY; STOMACH EMPTYING; STOMACH MOTILITY;

EID: 0030780325     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/030006059702500501     Document Type: Article

References (116)

1. Fioramonti J, Fargeas MJ, Buéno L: The involvement of opiate receptors in the effect of trimebutine on intestinal motility. J Pharm Pharmacol 1984; 36: 618-621.
2. Reynolds JC: Prokinetic agents: A key in the future of gastroenterology. Gastroenterol Clin North Am 1989; 18: 437-457.
3. Lüttecke K: A three part controlled study of trimebutine in the treatment of irritable colon syndrome. Curr Med Res Opin 1980; 6: 437-443.
4. Malavaud A: Essai de la trimébutine dans la reprise du transit digestif en chirurgie abdominale. A propos de 100 observations. Anesth Analg (Paris) 1972; 29: 65-69.
5. Hughes J: Opioid peptides. Br Med Bull 1983; 39: 1-106.
6. Hughes J, Smith TW, Kosterlitz HW, et al: Identification of two related pentapeptides from the brain with potent opiate agonist activity. Nature 1975; 258: 577-579.
7. Polak JM, Sullivan SN, Bloom SR: Enkephalin-like immunoreactivity in the human gastrointestinal tract. Lancet 1977; i: 972-974.
8. Houck JC, Chang CM, Kimball CD: Pancreatic beta-endorphin-like polypeptides. Pharmacology 1981; 23: 14-23.
9. Giros B, Gros C, Llorens-Cortes C, et al: Les peptides opioïdes: métabolisme et récepteurs. Gastroenterol Clin Biol 1987; 11: 7B-13B.
10. Simon EJ: Opioid receptors and opioid endogenous peptides. Med Res Rev 1991; 11: 356-374.
11. Bitar KN, Makhlouf GM: Selective presence of opiates receptors on intestinal circular muscle cells. Life Sci 1985; 37: 1545-1550.
12. Burks T: Gastrointestinal pharmacology. Annu Rev Pharmacol Toxicol 1976; 16: 15-31.
13. Manara L, Bianchetti A: The central and peripheral influences of opioids on gastrointestinal propulsion. Annu Rev Pharmacol Toxicol 1985; 25: 249-273.
14. Rattan S, Goyal RK: Identification and localization of opioid receptors in the opossum lower oesophageal sphincter. J Pharmacol Exp Ther 1983; 224: 391-397.
15. Buéno L, Fioramonti J: Action of opiates on gastrointestinal functions. Baillieres. Clin Gastroenterol 1988; 2: 123-139.
16. Nimmo WS, Heading RC, Wilson J, et al: Inhibition of gastric emptying and drug absorption by narcotic analgesics. Br J Clin Pharmacol 1975; 2: 509-513.
17. Sullivan SN, Lanki L, Corcoran P: Inhibition of gastric emptying by enkephalin analogue. Lancet 1981; 11: 86-87.
18. Edin R, Lundberg L, Terenius L, et al: Evidence for vagal enkephalinergic neural control of the feline pylorus and stomach. Gastroenterology 1980; 78: 492-497.
19. Fioramonti J, Fargeas MJ, Buéno L: Comparative effects of morphine and cyclazocine on gastrointestinal motility in conscious dogs. Arch Int Pharmacodyn Ther 1984; 270: 141-150.
20. Buéno L, Fioramonti J, Fargeas MJ, et al: Central and peripheral control of gastrointestinal and colonic motility by endogenous opiates in conscious dogs. Gastroenterology 1985; 88: 549-556.
21. Weisbrodt NW, Sussman SE, Stewart JJ, et al: Effects of morphine sulfate on intestinal transit and myoelectric activity of the small intestine of the rat. J Pharmacol Exp Ther 1980; 214: 333-338.
22. Gallagan JJ, Burks TF: Centrally mediated inhibition of small intestinal transit and motility by morphine in the rat. J Pharmacol Exp Ther 1983; 226: 356-361.
23. Sarna S, Orthcott P, Belbeck I: Mechanism of cycling of migrating myoelectric complexes: effect of morphine. Am J Physiol 1982; 242: G588-G595.
24. Buéno L, Ruckebush Y: Origine centrale de l'action excito-motrice de l'intestin par la morphine. C R Soc Biol 1978; 172: 972-977.
25. Waterfall WE, Beattie HW: Initiation of premature migrating myoelectrical complexes in man by morphine. Gastroenterology 1982; 82: 1207.
26. Buéno L, Fioramonti J, Ruckebush Y: Rate of flow digesta and electrical activity of the small intestine in dog and sheep. J Physiol (London) 1975; 249: 69-85.
27. Pinnington J, Wingate DL: In vivo modulation of small bowel motility by morphine and D-Ala2 D-Leu5 Enkephalin. Life Sci 1982; 31: 2217-2219.
28. Staumont G, Delvaux M, Fioramonti J, et al: Differences between jejunal myoelectric activity after a meal and during phase II of migrating motor complexes in healthy humans. Dig Dis Sci 1992; 37: 1554-1561.
29. Fioramonti J, Buéno L: Diurnal changes in colonic motor profile in conscious dogs. Dig Dis Sci 1983; 28: 257-264.
30. Buéno L, Fioramonti J, Ruckebush M: Comparative effects of morphine and nalorphine on colonic motility in conscious dogs. Eur J Pharmacol 1981; 75: 239-245.
31. Fioramonti J, Fargeas MJ, Buéno L: Stimulation of gastrointestinal motility by loperamide in dogs. Dig Dis Sci 1987; 32: 641-646.
32. Buéno L, Fioramonti J, Frexinos J, et al: Evaluation of colonic myoelectrical activity in health and functional disorders. Gut 1980; 27: 381-389.
33. Kreek MJ, Schaefer RA, Hann EF, et al: Naloxone, a specific opioid antagonist, reverses chronic idiopathic constipation. Lancet 1982; i: 261-262.
34. Sun EA, Snape WJ, Cohen S, et al: The role of opiate receptors and cholinergic neurons in the gastrocolonic response. Gastroenterology 1982; 82: 689-693.
35. Porecca F, Cowan A, Raffa RB, et al: Ketazocines and morphine effects on gastrointestinal transit after central and peripheral administration. Life Sci 1983; 32: 1785-1790.
36. Fioramonti J, Buéno L, Fargeas MJ: Enhancement of colonic motor response to feeding by central endogenous opiates in the dog. Life Sci 1985; 36: 2509-2514.
37. Van Nueten J, Van Ree JM, Van Houtte P: Inhibition by Met-enkephalin of peristaltic activity in the guinea pig ileum and its reversal by naloxone. Eur J Pharmacol 1977; 41: 341-342.
38. Paton WDM, Zar MA: The origin of acetylcholine released from guinea pig intestine and longitudinal muscle strips. J Physiol 1968; 194: 13-33.
39. North RA: Hyperpolarization of myenteric neurons by enkephalins. Br J Pharmacol 1977; 59: 504P-505P.
40. Zelter G: Antagonism of cholecystokinin-like peptides by opioid peptides, morphine and tetrodotoxin. Eur J Pharmacol 1979; 60: 67-77.
41. Collins SM, Daniel EE: Opiate modulation of gastrointestinal motility and the action of trimebutine. Can J Gastroenterol 1991; 5: 185-193.
42. Konturek SJ, Tasler J, Cieszkowski M, et al: Comparison of Met-enkephalin and morphine in the stimulation of gastric acid secretion in the dog. Gastroenterology 1980; 78: 294-300.
43. Kim MS, Faichney A, Chey WY, et al: Effect of Met-enkephalin on gastric acid secretion stimulated by a meat meal in dogs. (Abstract) Gastroenterology 1979; 76: 1169.
44. Skov Olsen P, Kirkegaard P, Petersen B, et al: The effect of a synthetic Metenkephalin analog (FK 33-824) on gastric acid secretion and serum gastrin in man. Scand J Gastroenterol 1981; 16: 531-533.
45. Roze C, Dubrasquet M, Chariot J, et al: Central inhibition of gastric and pancreatic secretions by β-endorphin in rats. Gastroenterology 1980; 79: 659-664.
46. Konturek SJ, Tasler J, Cieszkowski M, et al: Inhibition of pancreatic secretion by enkephalin and morphine in dogs. Gastroenterology 1978; 74: 851-855.
47. Mailman D: Effects of morphine on canine intestinal absorption and blood flow. Br J Pharmacol 1980; 68: 617-624.
48. Primi MP, Buéno L, Fioramonti J: Central regulation of intestinal and stimulated water and ion transport by endogenous opiates in dogs. Dig Dis Sci 1986; 31: 172-176.
49. Pascaud X, Roman F, Petoux F, et al: Action de la trimébutine sur la motricité gastro-intestinale. Gastroenterol Clin Biol 1987; 11: 77B-81B.
50. Allescher HD, Ahmad S, Classen M, et al: Interaction of trimebutine and JO-1196 (fedotozine) with opioid receptors in the canine ileum. J Pharmacol Exp Ther 1991; 257: 836-842.
51. Roman F, Pascaud X, Taylor JE, et al: Interactions of trimebutine with guinea pig opioid receptors. J Pharm Pharmacol 1987; 39: 404-407.
52. Taniyama K, Sano I, Nakayama S, et al: Dual effect of trimebutine on contractility of the guinea pig ileum via the opioid receptors. Gastroenterology 1991; 101: 1579-1587.
53. Buéno L, Honde C, Pascaud X, et al: Effects of orally versus parenterally administered trimebutine on gastrointestinal and colonic motility in dogs. Gastroenterol Clin Biol 1987; 11: 90B-93B.
54. Blanquet F, Bouvier M, Gonella J: Action of trimebutine in cat and rabbit colon: evidence of an opioid-like effect. J Pharmacol Exp Ther 1985; 234: 708-712.
55. Julé Y: Effets de la trimébutine sur la transmission cholinergique au niveau des neurones du ganglion mésentérique inférieur du lapin. Gastroenterol Clin Biol 1987; 11: 82B-85B.
56. Poitras P, Honde C, Havrankova J, et al: Effect of trimebutine on intestinal motility and plasma motilin in the dog. Am J Physiol 1986; 251: G349-G353.
57. Poitras P, Honde C, Goyer R, et al: Effet de la trimébutine sur la libération plasmatique post-prandiale d'hormones gastro-intestinales chez le chien. Gastroenterol Clin Biol 1987; 11: 94B-96B.
58. Nakada S: A study of peripheral VIP levels before and after administration of Cerekinon in patients with irritable bowel syndrome. Ther Res 1985; 3: 827-828.
59. Fraitag B, Hostein J, Pascaud X, et al: La trimébutine : pharmacologie, acquisitions récentes sur son mode d'action, résultats thérapeutiques. Gastroenterol Clin Biol 1992; 16: 413-420.
60. Yoshikawa M, Endo H, Oinogi Y, et al: Absorption, distribution and excretion of trimebutine maleate in rats, mice and dogs. Pharmacometrics 1982; 24: 289-314.
61. Diamant N: Enkephalinergic control of gastrointestinal motility: from "gut-brain" to trimebutine. Can J Gastroenterol 1987; 1: 41-43.
62. Suyama T, Miyoshi A, Hori R, et al: Studies on clinical effects of Trimebutine on gastric emptying time using double sampling method. Jpn Arch Intern Med 1980; 27: 159-167.
63. Harasawa S: Effects of Cerekinon on the gastric emptying. Ther Res 1985; 3: 782-787.
64. Dahan R, Leger P, Caulin C: Effet de cinq médicaments modificateurs de la motricité gastrique sur la vitesse d'evacuation d'un repas dyspeptogène chez l'homme sain. (Abstract) Gastroenterol Clin Biol 1984; 9: 24A.
65. Okano H, Saeki S, Inui A, et al: Effect of trimebutine maleate on emptying of stomach and gallbladder and release of gut peptides following a solid meal in man. Dig Dis Sci 1993; 38: 817-823.
66. Mazzone O, Trovato GM, Mandala ML, et al: Trimebutina e motilita gastrica: studio tensiografico. Clin Ter 1980; 95: 629-635.
67. Danne O, Bérard H, Mignon M, et al: Maléate de trimebutine et sécrétion gastrique chez l'homme sain. (Abstract) Gastroenterol Clin Biol 1987; 11: 267A.
68. Defilippi C, Gomez E: Effect of two prokinetic drugs on the electrical and motor activity of the small bowel in dogs. Aliment Pharmacol Ther 1993; 7: 327-330.
69. Diop L, Pascaud X, Le Gallou B, et al: Travel stress alters the intestinal myoelectric complex in rats: antagonistic effect of trimebutine. Life Sci 1992; 50: 263-271.
70. Grandjouan S, Chaussade S, Couturier D, et al: A comparison of metoclopramide and trimebutine on small bowel motility in humans. Aliment Pharmacol Ther 1989; 3: 387-393.
71. Chaussade S, Grandjouan S, Couturier D, et al: Induction of phase III of the migrating motor complex in human small intestine by trimebutine. Eur J Clin Pharmacol 1987; 32: 615-618.
72. Chaussade S, Bérard H, Chanoine F, et al: Effet de l'instillation intra-duodénale de trimébutine sur la motricité interdigestive chez l'homme. Gastroenterol Clin Biol 1988; 12: 864.
73. Couturier D, Chaussade S, Grandjouan S: Effet de la trimebutine sur la motricité de l'intestin grêle chez l'homme (English abstract). Presse Med 1989; 18: 303-307.
74. Funakoshi A, Shinozaki H, Nakano I, et al: The effect of trimebutine on the secretion of gastrointestinal hormones in healthy volunteers. Cur Ther Res 1986; 40: 345-353.
75. Hamada Y, Kamyia K, Koyama M, et al: Studies on the clinical significance concerning the changes of serum pepsinogen I and gastrin levels in aged patients with chronic gastritis. Hokkaido Igaku Zasshi 1988; 63: 178-185.
76. Moshal MG, Herron M: A clinical trial of trimebutine in spastic colon. J Int Med Res 1979; 7: 231-234.
77. Schang JC, Devroede G, Pilote M: Beneficial effects of trimebutine in patients suffering from irritable bowel disease with normal transit and constipation (abstract). Gastroenterology: 1988; 94: A403.
78. Valori R, Shannon S, Reddy N, et al: The action of trimebutine maleate on gastrointestinal motility is mediated by opiate receptors in human subjects. Gastroenterol Clin Biol 1987; 11: 102B-104B.
79. Frexinos J, Fioramonti J, Buéno L: Effect of trimebutine on colonic myoelectrical activity in IBS patients. Eur J Clin Pharmacol 1985; 28: 181-185.
80. Meunier P: Effet de la trimébutine sur la motricité colique dans les colopathies. Gastroenterol Clin Biol 1980; 4: 261A.
81. Reboa G, Bertoglio C, Terrizzi A, et al: L'azione della trimebutina sull'attivita elettrica e manometrica del colon normale e patologico. Riv Gastroenterol 1976; 28: 1-16.
82. Shannon S, Hollingsworth J, Cook IJ, et al: Effect of trimebutine on post-prandial colonic motor activity in healthy subjects and patients with irritable bowel syndrome. J Gastrointest Mot 1989; 1: 9-14.
83. Matsueda K, Yamato S, Shoda R, et al: Effect of trimebutine-maleate on gastrocolic reflex in patients with irritable bowel syndrome (abstract). Gastroenterology 1989; 96: 327A.
84. Gué M, Hondé C, Pascaud X, et al: CNS blockade of acoustic stress-induced gastric motor inhibition in fasted dogs. Am J Physiol 1988; 17: G802-G807.
85. Fioramonti J, Buéno L: Colonic myoelectrical activity and propulsion in the dog. Dig Dis Sci 1980; 25: 641-646.
86. Valori RM, Kumar D, Wingate DL: Effects of different types of stress and "prokinetic" drugs on the control of the fasting motor complex in humans. Gastroenterology 1986; 90: 1890-1900.
87. Gué M, Fioramonti J, Frexinos J, et al: Influence of acoustic stress by noise on gastrointestinal motility in dogs. Dig Dis Sci 1987; 32: 1411-1417.
88. Gué M, Pascaud X, Hondé C, et al: Peripheral antagonistic action of trimebutine and kappa opioid substances on acoustic stress-induced gastric motor inhibition in dogs. Eur J Pharmacol 1988; 146: 57-63.
89. Delis C, Walker EA, Castillo FD, et al: The effect of stress and opioid agonist on postprandial motor activity in the human small bowel. Digestive disease week, AGA, New Orleans, USA, 15-18 May 1994 (abstract). Gastroenterology 1994; 106: A 485.
90. Bradette M, Delvaux M, Staumont G, et al: Evaluation of colonic sensory thresholds in IBS patients using a barostat: definition of optimal conditions and comparisons with healthy subjects. Dig Dis Sci 1994; 39: 449-457.
91. Bradette M, Delvaux M, Staumont G, et al: Octreotide increases thresholds of colonic visceral perception in IBS patients. Dig Dis Sci 1994; 39: 1171-1178.
92. Julia V, Couranjou MC, Auriol P, et al: Evaluation comparée des propriétés antagonistes de la trimébutine, du citrate d'alvérine et du granisétron vis-à-vis du réflexe recto-colique inhibiteur chez le rat vigile. Proceedings: Club Français de Motricité Digestive, Lyon, 24-25 Juin 1993, p. 3.
93. Julia V, Coelho AM, Rouzade MI, et al: Influence de la trimébutine (Débridat) sur l'hypomotricité colique et les crampes abdominales liées à la distension rectale chez le rat. Med Chir Dig 1996; 25: 239-242.
94. Bommelaer G, Rouch M, Dapoigny M, et al: Epidemiologie des troubles fonctionnels intestinaux dans une population saine. Gastroenterol Clin Biol 1986; 10: 7-12.
95. Thompson WG: Symptomatic presentations of the irritable bowel syndrome. Gastroenterol Clin North Am 1991; 20: 235-248.
96. Staumont G, Fioramonti J, Delvaux M, et al: Glycerol induced colic is associated to a stimulation of colonic myoelectrical activity in man. Gastroenterology 1989; 96: A489.
97. Lüttecke K: A trial of trimebutine in spastic colon. J Int Med Res 1978; 6: 86-88.
98. Lüttecke K: A three part controlled study of trimebutine in the treatment of irritable colon syndrome. Curr Med Res Opin 1980; 6: 437-443.
99. Schaffstein W, Panijel M, Lüttecke K: Comparative safety and efficacy of trimebutine versus mebeverine in the treatment of irritable bowel syndrome. Curr Ther Res 1990; 47: 136-145.
100. Toussaint J, Cremer M, Pintens H: Etude en simple aveugle de trimébutine et de la mébévérine dans le côlon irritable et la dyspepsie. Acta Ther 1981; 7: 261-268.
101. Fielding JF: Double-blind trial of trimebutine in the irritable bowel syndrome. Ir Med J 1980; 73: 377-379.
102. Ghidini O, Saponati G, Intrieri L: Single drug treatment for irritable colon: rociverine versus trimebutine maleate. Curr Ther Res 1986; 39: 541-548.
103. Lee SW, Kim IS, Song JH, et al: Clinical trial of polybutine (trimebutine maleate) in patients with irritable colon syndrome. N Med J (Seoul) 1981; 24: 52-59.
104. Schang JC, Devroede G, Pilote M: Effect of trimebutine on colonic function in patients with chronic idiopathic constipation: evidence for the need of a physiologic rather than clinical selection. Dis Colon Rectum 1993; 36: 330-336.
105. Grenier JF, Vaxman F, Becmeur F: Activité de la trimébutine dans la colopathie fonctionnelle. Essai clinique multicentrique. Est Médecine 1986; 6: 169-172.
106. Walters JM, Crean P, McCarthy CF: Trimebutine, a new antispasmodic in the treatment of dyspepsia. Ir Med J 1980; 73: 380-381.
107. Nebiacolombo C, Borgonovo G, Puglisi M: The treatment of dyspeptic syndromes. Controlled clinical experiments on enzymatic Debridat. Int J Clin Pharmacol Res 1982; 2: 21-27.
108. Abei T, Isogai S, Onuki T, et al: A multiinstitutional double-blind control study to compare the effectiveness of TM-906 and metoclopramide on controlling functional gastrointestinal symptoms. Clin Evaluat 1977; 5: 189-203.
109. Caldeira ML, Palombo G: Avaliacào clinica da trimebutine ni ileo paralitico posöperatório (English abstract). Folha Med 1980; 81: 229-232.
110. Akhoue Y, Chaussade S, Guerre J, et al: Manométrie de l'intestin grêle dans le diagnostic des maladies motrices de l'intestin grêle : intérêt d'une stimulation pharmacologique par la trimébutine. (abstract) Gastroenterol Clin Biol 1990; 14: A10.
111. Parent P, LeFur JM, Castel Y: Effets thérapeutiques du Débridat chez l'enfant. Ouest Med 1982; 35: 781-783.
112. Dupont C: Effet du Débridat (Trimébutine) dans les colopathies fonctionnelles de l'enfant. Médecine Enfance 1982; 2: 6.
113. Boige N, Cargill G, Mashako L, et al: Trimebutine-induced phase III-like activity in infants with intestinal motility disorders. J Pediatr Gastroenterol Nutr 1987; 6: 548-553.
114. Corazza GR, Vaira M, Milletti S, et al: Controlled clinical evaluation of pinaverium bromide and trimebutine in functional disorders of the colon. Acta Ther 1983; 9: 383-389.
115. Assisi R, Bayeli PF, Boggiano CA, et al: Attività terapeutica della fenoverina in pazienti con colon irritabile: ricerca clinica policentrica. Riforma Med 1988; 103: 345-350.
116. Miyoshi A, Yachi A, Kawakami K, et al: The clinical effects of cisapride on digestive symptoms. A double-blind study, Jpn Arch Intern Med 1987; 34: 289-313.